SYBX vs. MEIP, LSTA, TXMD, LUMO, BFRG, BIOR, CPIX, INDP, ONCT, and ONTX
Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include MEI Pharma (MEIP), Lisata Therapeutics (LSTA), TherapeuticsMD (TXMD), Lumos Pharma (LUMO), Bullfrog AI (BFRG), Biora Therapeutics (BIOR), Cumberland Pharmaceuticals (CPIX), Indaptus Therapeutics (INDP), Oncternal Therapeutics (ONCT), and Onconova Therapeutics (ONTX). These companies are all part of the "pharmaceutical preparations" industry.
MEI Pharma (NASDAQ:MEIP) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
MEI Pharma received 42 more outperform votes than Synlogic when rated by MarketBeat users. However, 69.54% of users gave Synlogic an outperform vote while only 60.55% of users gave MEI Pharma an outperform vote.
MEI Pharma has a net margin of 39.06% compared to MEI Pharma's net margin of -1,699.23%. Synlogic's return on equity of 39.72% beat MEI Pharma's return on equity.
MEI Pharma presently has a consensus price target of $7.00, indicating a potential upside of 114.72%. Synlogic has a consensus price target of $65.00, indicating a potential upside of 3,357.45%. Given MEI Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Synlogic is more favorable than MEI Pharma.
52.4% of MEI Pharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 3.9% of MEI Pharma shares are owned by insiders. Comparatively, 8.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, MEI Pharma and MEI Pharma both had 1 articles in the media. MEI Pharma's average media sentiment score of 0.36 beat Synlogic's score of 0.00 indicating that Synlogic is being referred to more favorably in the news media.
MEI Pharma has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
MEI Pharma has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Synlogic beats MEI Pharma on 9 of the 17 factors compared between the two stocks.
Get Synlogic News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synlogic Competitors List
Related Companies and Tools
